These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 25494820)

  • 1. The potential role of PD0332991 (Palbociclib) in the treatment of multiple myeloma.
    Altenburg JD; Farag SS
    Expert Opin Investig Drugs; 2015 Feb; 24(2):261-71. PubMed ID: 25494820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.
    Roberts PJ; Bisi JE; Strum JC; Combest AJ; Darr DB; Usary JE; Zamboni WC; Wong KK; Perou CM; Sharpless NE
    J Natl Cancer Inst; 2012 Mar; 104(6):476-87. PubMed ID: 22302033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palbociclib (PD0332991)-a Selective and Potent Cyclin-Dependent Kinase Inhibitor: A Review of Pharmacodynamics and Clinical Development.
    Clark AS; Karasic TB; DeMichele A; Vaughn DJ; O'Hara M; Perini R; Zhang P; Lal P; Feldman M; Gallagher M; O'Dwyer PJ
    JAMA Oncol; 2016 Feb; 2(2):253-60. PubMed ID: 26633733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.
    DeMichele A; Clark AS; Tan KS; Heitjan DF; Gramlich K; Gallagher M; Lal P; Feldman M; Zhang P; Colameco C; Lewis D; Langer M; Goodman N; Domchek S; Gogineni K; Rosen M; Fox K; O'Dwyer P
    Clin Cancer Res; 2015 Mar; 21(5):995-1001. PubMed ID: 25501126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palbociclib: A new hope in the treatment of breast cancer.
    Palanisamy RP
    J Cancer Res Ther; 2016; 12(4):1220-1223. PubMed ID: 28169231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin-dependent kinase pathways as targets for women's cancer treatment.
    Konecny GE
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):42-8. PubMed ID: 26642065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The safety and efficacy of palbociclib in the treatment of metastatic breast cancer.
    Ettl J; Harbeck N
    Expert Rev Anticancer Ther; 2017 Aug; 17(8):661-668. PubMed ID: 28649895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiproliferative effects of the CDK6 inhibitor PD0332991 and its effect on signaling networks in gastric cancer cells.
    Wang D; Sun Y; Li W; Ye F; Zhang Y; Guo Y; Zhang DY; Suo J
    Int J Mol Med; 2018 May; 41(5):2473-2484. PubMed ID: 29436583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer.
    Rocca A; Farolfi A; Bravaccini S; Schirone A; Amadori D
    Expert Opin Pharmacother; 2014 Feb; 15(3):407-20. PubMed ID: 24369047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors.
    Vaughn DJ; Hwang WT; Lal P; Rosen MA; Gallagher M; O'Dwyer PJ
    Cancer; 2015 May; 121(9):1463-8. PubMed ID: 25522918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma.
    Mahgoub T; Eustace AJ; Collins DM; Walsh N; O'Donovan N; Crown J
    Int J Oncol; 2015 Sep; 47(3):900-8. PubMed ID: 26201960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting CDK4/6 in patients with cancer.
    Hamilton E; Infante JR
    Cancer Treat Rev; 2016 Apr; 45():129-38. PubMed ID: 27017286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.
    Baughn LB; Di Liberto M; Wu K; Toogood PL; Louie T; Gottschalk R; Niesvizky R; Cho H; Ely S; Moore MA; Chen-Kiang S
    Cancer Res; 2006 Aug; 66(15):7661-7. PubMed ID: 16885367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.
    Dickson MA; Tap WD; Keohan ML; D'Angelo SP; Gounder MM; Antonescu CR; Landa J; Qin LX; Rathbone DD; Condy MM; Ustoyev Y; Crago AM; Singer S; Schwartz GK
    J Clin Oncol; 2013 Jun; 31(16):2024-8. PubMed ID: 23569312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of the CDK4/6 inhibitor palbociclib (PD 0332991) and its future application in cancer treatment (Review).
    Liu M; Liu H; Chen J
    Oncol Rep; 2018 Mar; 39(3):901-911. PubMed ID: 29399694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model.
    Menu E; Garcia J; Huang X; Di Liberto M; Toogood PL; Chen I; Vanderkerken K; Chen-Kiang S
    Cancer Res; 2008 Jul; 68(14):5519-23. PubMed ID: 18632601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular pathways: CDK4 inhibitors for cancer therapy.
    Dickson MA
    Clin Cancer Res; 2014 Jul; 20(13):3379-83. PubMed ID: 24795392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palbociclib (Ibrance) for metastatic breast cancer.
    Med Lett Drugs Ther; 2015 Aug; 57(1475):115-6. PubMed ID: 26262882
    [No Abstract]   [Full Text] [Related]  

  • 20. Preclinical and clinical development of palbociclib and future perspectives.
    de Dueñas EM; Gavila-Gregori J; Olmos-Antón S; Santaballa-Bertrán A; Lluch-Hernández A; Espinal-Domínguez EJ; Rivero-Silva M; Llombart-Cussac A
    Clin Transl Oncol; 2018 Sep; 20(9):1136-1144. PubMed ID: 29564714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.